Recent advances in multiple myeloma therapy

Recent advances in non-Hodgkin’s lymphoma therapy

BTK inhibitor PCI-32765 induces durable responses in relapsed or refractory chronic lymphocytic leukaemia/small lymphocytic lymphoma

Obinutuzumab with rituximab in patients with relapsed CD20 and indolent B-Cell non-hodgkin lymphoma (GAUSS)

ABVD chemo with radiation therapy for limited-stage hodgkin lymphoma

Two rituximab dosing strategies for low tumour burden follicular lymphoma (RESORT)

Cereblon expression required for anti-myeloma activity of lenalidomide and pomalidomide

The latest for Multiple Myeloma

Myelodysplastic syndrome drug development and combination therapy

Clinical trial data on treatment of chronic lymphocytic leukaemia with PCI-32765

Update and new perspectives in the management of MDS

New data on aggressive B cell lymphoma

Causes and drug development in ataxia telangiectasia

Update on the phase III VISTA trial

Update on the development of proteasome inhibitors

Romidepsin treatment in peripheral T cell lymphoma and subsets

Optimal treatment schedule for pomalidomide in multiple myeloma

Indolent non-Hodgkin’s Lymphoma in 2011: A game changing year

The changing landscape for NHL treatment

Novel agents and proteasome inhibitors in myeloma

Advances in peripheral T-cell lymphoma

Final results of the phase 3 VISTA trial: bortezomib-melphalan-prednisone (VMP) vs melphalan-prednisone (MP) for multiple myeloma

Translational research and proteasome inhibitors in multiple myeloma

Developments in proteasome inhibitors, transplant and myeloma research

Genomic study of acute myeloid leukaemia

GIMEMA study compares bortezomib-thalidomide-dexamethasone with thalidomide-dexamethasone prior to double autologous stem-cell transplantation

Lenalidomide with melphalan + prednisone and lenalidomide maintenance for multiple myeloma